Improved therapeutic outcomes of DHBCL after introduction of rituximab in Korean patients.
- 도영록; 송홍석
- Alternative Author(s)
- Do, Young Rok; Song, Hong Suk
- Publication Year
- The addition of rituximab to cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) has been
shown to improve the outcome in all age groups with
newly diagnosed diffuse large B-cell lymphoma (DLBCL).
We conducted a retrospective analysis to evaluate the
impact of this combination therapy on DLBCL outcomes in
Korea. From October 2001 to June 2004, newly diagnosed
DLBCL patients in nine Korean institutes were included.
All of these 81 patients were treated with three or more
cycles of rituximab plus CHOP (R-CHOP) combination
chemotherapy (R group), and followed for a minimum of
12 months. For comparison, a historical cohort of patients
was used and analyzed for “Clinicopathologic characteristics
of Korean non-Hodgkin’s lymphomas (NHLs) based
on Revised American Lymphoma (REAL) classification”
in 1999. Among the 1,098 NHL patients, the data of 214
DLBCL patients, who were treated with CHOP chemotherapy
in first-line, were analyzed (C group). We
compared outcomes between the C group and the R
group. A total of 295 patients were evaluated (C group,
214; R group, 81). The complete response (CR) rate was
higher in R group (73 vs 91%, p=0.001). The 2-year eventfree
survival (EFS) rate was significantly higher in R group
(78 vs 85%, p=0.0194). This survival benefit was maintained
in high-risk patients according to the international
prognostic index (IPI) (p=0.0039), regardless of age.
However, there was no significant difference in low-risk
patients. The addition of rituximab to CHOP combination
chemotherapy for DLBCLs showed improved outcomes,
particularly in high-risk group according to the IPI. Longterm
follow-up results will be needed to confirm these
Keywords Rituximab . CHOP . DLBCL
- Authorize & License
- Files in This Item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.